Before the market opened on Wednesday, Hibbett Inc. HIBB, -0.12% reported a better-than-expected profit, but sales were lower than what analysts had expected. For the quarter, the sporting goods store made $32.5 million, or $2.67 per share. This is down from $35.9 million, or $2.74 per share, during the same time last year. FactSet polled analysts and found that they expected the company to make $2.58 per share. Sales dropped from $455.5 million in the same quarter last year to $447.2 million this year. FactSet polled analysts, and they thought sales would be $452.9 million. Shares of Hibbett are down 0.6% before the market opens. “In a very tough athletic footwear and apparel retail market, our sales and diluted earnings per share for the first quarter of Fiscal 2025 were in line with our expectations,” Hibbett CEO Mike Longo said in prepared remarks. Same-store sales at Hibbett’s went down 5.8%. FactSet polled analysts and found that they were expecting a 4.3% drop. The Alabama-based company that sells sportswear did not change its previously issued financial guidance because it was still working on a deal with JD Sports Fashion. JD Sports JD, +0.57% said in April that it would buy Hibbett for $1.1 billion. In 2024, Hibbett shares are up 19.8%, which is more than the 10.9% gain in the S&P 500 index (SPX, +0.15%).
🔴
Trending
- Waller of the Fed supports a rate drop in December and says he is “unlikely” to change his opinion. Here’s why.
- Trump and Mamdani claim to agree on lowering living expenses, particularly the rates charged by a large electricity firm.
- To boost their incomes, Treasury Secretary Bessent encourages Americans to take this easy step. Do you think you should do it?
- The November inflation data was postponed until after the Fed’s next significant interest-rate vote, and the October CPI was canceled.
- These AI stocks appeal to the fund manager who “pounded the table” to acquire Nvidia in 2017.
- Alphabet’s stock increases as much as it can. A new development in the AI commerce is highlighted by the meta chip deal.
- Are the “Magnificent Seven” coming to an end? Pay special attention to these three stocks.
- GLP-1 medications may still be able to slow the second most common form of dementia.

